Loading clinical trials...

Study Comparing Tigecycline to Imipenem/Cilastatin in Complicated Intra-Abdominal Infections in Hospitalized Subjects | Clinical Trials | Clareo Health

COMPLETEDPHASE3

Study Comparing Tigecycline to Imipenem/Cilastatin in Complicated Intra-Abdominal Infections in Hospitalized Subjects

A Multicenter, Double-Blind, Randomized Comparison Study Of the Efficacy and Safety of Tigecycline to Imipenem/ Cilastatin to Treat Complicated Intra-Abdominal Infections in Hospitalized Subjects

NCT00081744•Wyeth is now a wholly owned subsidiary of Pfizer

View on ClinicalTrials.gov

Summary

Purpose: To provide a mechanism for the emergency use of tigecycline in the appropriate clinical situations.

Eligibility

Age

8 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Male or female subjects, ≥ 8 years of age and a weight of ≥ 35 kilograms
•Subjects with selected culture-positive infections caused by a multiple antibiotic-resistant pathogen presumed to be susceptible to tigecycline
•Subjects who have failed or are intolerant of other available appropriate antibiotic therapies or whose pathogens are resistant to other available antibiotics

Exclusion Criteria

•Subjects who are moribund with an expected survival of less than 2 weeks.
•Subjects who have been designated as "Do Not Resuscitate", unless it is anticipated within a reasonable degree of medical certainty that they can achieve benefit from potentially curative antibiotic therapy
•Known or suspected hypersensitivity to tigecycline, tetracyclines, or other compounds related to this class of antibacterial agents

Key Dates

Start Date

November 1, 2002

Primary Completion Date

August 1, 2004

Completion Date

August 1, 2004

Last Updated

February 8, 2013

Enrollment

850

ACTUAL participants

Conditions

Gram-Positive Bacterial InfectionsCross Infection

Interventions

Tigecycline

DRUG

Drug Exposure and Minimum Inhibitory Concentration in the Treatment of MAC Lung Disease

NCT05824988

Mycobacterium Avium ComplexMycobacterium Avium-Intracellulare Infection+2 more

View study

COMPLETEDNA

Clinical Decision Support Tool for Vancomycin Dosing in Children

NCT04911270

Gram-Positive Bacterial InfectionsVancomycin+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 8, 2013Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Study Comparing Tigecycline to Imipenem/Cilastatin in Complicated Intra-Abdominal Infections in Hospitalized Subjects

Inclusion Criteria

Exclusion Criteria

Drug Exposure and Minimum Inhibitory Concentration in the Treatment of MAC Lung Disease

Clinical Decision Support Tool for Vancomycin Dosing in Children

Reuse of Polyp Traps, a Way to Approach Sustainability

TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection

Cross Transmissions of Pseudomonas Aeruginosa Between Children From a Same Cystic Fibrosis Center.

Telavancin for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia